Lupus

Stay updated with the latest healthcare breakthroughs, including new phase 2/3 clinical trial data and an FDA approval, in this week's essential news roundup.

With the approval, children ≥ 5 years of age with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration.

Recent studies reveal belimumab's effectiveness in treating lupus nephritis, showing significant renal response and improved patient outcomes in real-world settings.

New analysis reveals obinutuzumab's potential to improve kidney inflammation and biomarkers in lupus nephritis.

A recent study reveals significant variations in biologic use among pregnant patients with autoimmune diseases, highlighting the need for tailored risk-benefit assessments.

EMD Serono previously announced that its CLE cohort had met its primary endpoint while its SLE cohort failed to follow suit.

A recent meta-analysis confirms belimumab's superior efficacy over placebo in treating systemic lupus erythematosus, potentially informing clinical management strategies.

The filing acceptance is based on positive data from the phase 3 REGENCY study. A decision on the approval is expected by October 2025.

Use of obinutuzumab was associated with significant improvements in complete renal response rate and markers of disease activity in active lupus nephritis.

ADI-001 now has FDA Fast Track Designation for relapsed/refractory lupus nephritis and systemic lupus erythematosus with extrarenal involvement.

Cell therapy, particularly CAR-T, is expanding into autoimmune diseases like lupus and multiple sclerosis. While promising, safety, efficacy, and broad applicability remain uncertain.

The GLEAM trial is currently enrolling patients to receive SC291, with data expected in 2025.

Patients in the anifrolumab arm also had lower rates of damage accrual.

Hypovitaminosis D was more prevalent in patients with lupus nephritis compared to patients with systemic lupus erythematosus without kidney disease.

Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.

The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.

A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

A study found that high ultraprocessed food consumption increases the risk of SLE by 56%, with an even higher risk for anti-dsDNA positive SLE at 105%.

The therapy demonstrated superior efficacy in combination with SOC over SOC alone.

Concomitantly, other treatment modalities such as physical and occupational therapy, anticonvulsants, topical analgesics, and psychosocial treatment have increased.

Those with limited health literacy had higher disease activity and more SLE damage.

The study highlighted the potential role of shared decision-making in building trust in physicians among patients with SLE.

Results from a Mendelian randomization analysis indicate type 1 diabetes significantly increases the likelihood of autoimmune conditions like rheumatoid arthritis and multiple sclerosis.